Investment Q&A

Q: Good Morning
I have held Vitalhub in my TFSA for some time with no reward for my patience. Although it seems they are making progress, much like WELL they don’t seem to get any recognition from the markets. Would you endorse a switch to DOO, CTS or another name from the Growth Portfolio? Or is more patience warranted given their latest quarterly results?
Thank you

Q: Could you comment on the latest contract signed by VHI which equates to about 7% of their market cap? Thanks as always.

TORONTO, June 06, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSX: VHI) is pleased to announce that TREAT has been licensed for an initial six-year contract term and an option to extend for four additional years, to better track the essential medical information needed to effectively treat inmates in provincially-run adult correctional institutions across Ontario.

For VitalHub, this agreement is an important and meaningful event. The six-year contract value is comprised of recurring license revenue and professional services delivered over a six-year period, totaling approximately $9 million (CAD) in the initial term.

Q: Please comment on their earnings and why you feel the shares pulled back on the results when it appeared like a good quarter.

Q: Your opinions please on Vitalhub following their latest quarter.
Thank you

Q: Hi Peter and team, I don't hold any of the above stocks and they have done very well the last 2 years. I do own some of your favorites like BAM, TOI, CUS, SHOP and LSPD etc. How would you rank the above stocks and would they be good buy when the dust finally settles.

Regards
Anthony

Q: Please rank these telemedicine stocks as likely (1) survivor and consolidator, (2) acquiree, (3) flash in the pan and eventually bankrupt. Please include any other Canadian telemedicine stocks that I missed in this list.

Q: Comments on earnings and your opinions going forward.
Thank you

Q: What is your thoughts on the quarter?

Q: The share price for Vitahub Corp has dropped about 30% from the peak since June 2021 and it seems to continue dropping. What are the reasons for the downtrend? Is this stock a buy, hold or sell considering the next 1 to 2 year performance?

Q: We have very little tech. exposure in our portfolios as a % - so minimal. Own IGM & ARKK in USD portfolio - IGM for 4 years - done very well. In TFSA, own STC, VHI, XIT ETF. All the others are on my list to purchase as not. I would buy equal positions - so, of those we do not own which three would you consider the best in the short and long term. I am mostly a dividend grower investor - companies that increase them every year; however, trying to add a bit of tech. Maybe there others not shown that meet my criteria?

Q: Of the 3, which do you see with greatest growth potential? Is there any overlap in owning all 3 that would make one expendable?

Q: Would appreciate your assessment of their Q1 earnings that were released this morning. At first glance, they look to be pretty reasonable.

Thanks as always

Q: Could you please provide your comments regarding the above companies. How would you rank them in terms of a 3 year hold as regards risk/growth possibilities.

Thanks

David

Q: Could I have your thoughts on Vitalhub's most recent acquisition of UK based S12 Solutions .
Thank-you.

Q: Your comments please on Vitalhub’s quarter and opinion moving forward.
Thank you

Q: I follow Jason Donville and like 5iresearch recommends similar tech companies as 5i using "the rule of 40". Do you use this rule? Other than his fairly transparent newsletter, is there any way to see exactly what his holdings are in the DKAM Capital Ideas fund?

Q: If you were to invest in just one of these companies, which one would you choose and why?

Q: Hi, with the announcement of Dialogue's future IPO, can you explain the differences between these 4 companies? Also, do you know the date of Dialogue's IPO?

Thank you
André

Q: Could you please comment on VHI's latest licensing deal.
Thanks as always.

VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce a multi-year large-scale licensing transaction of recently acquired subsidiary Intouch with Health’s (“Intouch”) Synopsis product with South Tees Hospitals NHS Foundation Trust (the “Trust” or “South Tees”).

This transaction is among VitalHub’s largest to-date, comprising a 5-year licensing contract for the Company’s proprietary, award-winning Synopsis platform. From initial questionnaire through to post-operative outcomes, Synopsis provides the necessary tools to enable hospitals to manage the entire pre-operative assessment process digitally – removing paper trails, increasing data security, and delivering significant organizational and economic benefits.

Q: If you had to pick 1, which would you choose and why?
Thx